- Home
- CR vs BMRN Comparison
CR vs BMRN Comparison
Compare CR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | BMRN |
|---|---|---|
| Founded | 1855 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.0B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CR | BMRN |
|---|---|---|
| Price | $187.48 | $59.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $223.20 | $89.74 |
| AVG Volume (30 Days) | 299.0K | ★ 3.1M |
| Earning Date | 01-26-2026 | 10-27-2025 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | 37.96 | ★ 59.53 |
| EPS | ★ 6.25 | 2.68 |
| Revenue | $2,268,100,000.00 | ★ $3,094,001,000.00 |
| Revenue This Year | $10.83 | $13.35 |
| Revenue Next Year | $14.14 | $9.06 |
| P/E Ratio | $34.33 | ★ $22.36 |
| Revenue Growth | ★ 19.64 | 12.39 |
| 52 Week Low | $127.04 | $50.76 |
| 52 Week High | $203.89 | $73.51 |
Technical Indicators
Market Signals| Indicator | CR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 63.83 |
| Support Level | $182.87 | $51.50 |
| Resistance Level | $189.50 | $61.79 |
| Average True Range (ATR) | 3.58 | 1.97 |
| MACD | -0.00 | 0.84 |
| Stochastic Oscillator | 43.45 | 69.36 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.